ERYP Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 jun 2023 @ 21:48):

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States...

Stats
Dagens volum	3 205.00
Gjennomsnittsvolum	148 586
Markedsverdi	47.38M
EPS	$0 ( 2023-04-26 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-78.00
ATR14	$0.108 (13.85%)

Volum Korrelasjon

Lang: 0.13 (neutral)

Kort: -0.16 (neutral)

Signal:(42.503) Neutral

Erytech Pharma S.A. Korrelasjon

10 Mest positive korrelasjoner
DGHI	0.897
ITMR	0.884
AVEO	0.874
SOHON	0.868
CHDN	0.859
DVCR	0.851
SOHOB	0.848
XLO	0.847
BTBT	0.846
KIN	0.846

10 Mest negative korrelasjoner
AMRB	-0.873
SABS	-0.861
ORRF	-0.857
VTIP	-0.857
TRIB	-0.846
POLA	-0.837
SGMA	-0.833
SOPA	-0.816
MMAC	-0.814
LFMD	-0.809

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Erytech Pharma S.A. Korrelasjon - Valuta/Råvare

-0.24
( neutral )

-0.31
( neutral )

0.00
( neutral )

-0.17
( neutral )

0.15
( neutral )

0.11
( neutral )

Erytech Pharma S.A. Økonomi

Annual	2022
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-0.00740

FY	2022
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-0.00740

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-2.68

FY	2020
Omsetning:	$0.00
Bruttogevinst:	$-57.58M (0.00 %)
EPS:	$-3.65

Financial Reports:

No articles found.

Erytech Pharma S.A.

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.